These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33788150)

  • 1. Differentiation of benign thyroid nodules from malignant thyroid nodules through miR-205-5p and thyroid-stimulating hormone receptor mRNA.
    Zhou J; Cao L; Chen Z
    Hormones (Athens); 2021 Sep; 20(3):571-580. PubMed ID: 33788150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
    Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
    Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
    Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
    BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation.
    Araujo PP; Marcello MA; Tincani AJ; Guilhen AC; Morari EC; Ward LS
    Pathol Res Pract; 2012 Aug; 208(8):489-92. PubMed ID: 22770943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting thyrotropin receptor mRNA from peripheral blood of patients with differentiated thyroid cancer rules out non-aggressive cases.
    Janković Miljuš JR; Prosenc Zmrzljak U; Košir R; Jovanović M; Đorić IĐ; Rončević JV; Išić Denčić TM; Šelemetjev SA
    Ann Clin Biochem; 2024 Sep; 61(5):338-346. PubMed ID: 38195090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
    Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
    Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
    Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
    Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations.
    Macerola E; Poma AM; Proietti A; Rago T; Romani R; Vignali P; Ugolini C; Torregrossa L; Basolo A; Santini F; Basolo F
    Endocrine; 2022 Jun; 76(3):677-686. PubMed ID: 35347579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of thyroid-stimulating hormone receptor mRNA with real-time PCR for early diagnosis of papillary thyroid microcarcinoma.
    Qiu J; Zhang Y; Guo X; Zeng F; Zhao C; Qiu X; Wu X
    Neoplasma; 2010; 57(4):360-4. PubMed ID: 20429628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management.
    Panebianco F; Mazzanti C; Tomei S; Aretini P; Franceschi S; Lessi F; Di Coscio G; Bevilacqua G; Marchetti I
    BMC Cancer; 2015 Nov; 15():918. PubMed ID: 26581891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
    Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
    J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.
    Yu S; Liu Y; Wang J; Guo Z; Zhang Q; Yu F; Zhang Y; Huang K; Li Y; Song E; Zheng XL; Xiao H
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2084-92. PubMed ID: 22472564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
    Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
    Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic and prognostic role of miR-146b-5p in differentiated thyroid carcinomas.
    Ferraz C; Cunha GB; de Oliveira MMB; Tenório LR; Cury AN; Padovani RDP; Ward LS
    Front Endocrinol (Lausanne); 2024; 15():1390743. PubMed ID: 39036050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations.
    Mon SY; Riedlinger G; Abbott CE; Seethala R; Ohori NP; Nikiforova MN; Nikiforov YE; Hodak SP
    Diagn Cytopathol; 2018 May; 46(5):369-377. PubMed ID: 29516685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
    Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
    J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma.
    Zhou C; Li J; Wang Y; Xue S; Zhang Y
    Oncol Lett; 2019 Jan; 17(1):183-194. PubMed ID: 30655754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.
    Aliyev A; Gupta M; Nasr C; Hatipoglu B; Milas M; Siperstein A; Berber E
    Endocr Pract; 2015 Jul; 21(7):777-81. PubMed ID: 25786552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and change of miR-199b-5p, s HLA-G in thyroid carcinoma.
    Tan B; Guo J; Wang L; Wang L; Gan X; Chen B
    Exp Mol Pathol; 2021 Jun; 120():104643. PubMed ID: 33932399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.